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ABSTRACT The rising frequency of multidrug-resistant and extensively drug-
resistant (MDR/XDR) pathogens is making more frequent the inappropriate em-
pirical antimicrobial therapy (IEAT) in nosocomial pneumonia, which is associated
with increased mortality. We aim to determine the short-term benefits of appro-
priate empirical antimicrobial treatment (AEAT) with ceftolozane/tazobactam
(C/T) compared with IEAT with piperacillin/tazobactam (TZP) in MDR Pseudomo-
nas aeruginosa pneumonia. Twenty-one pigs with pneumonia caused by an XDR
P. aeruginosa strain (susceptible to C/T but resistant to TZP) were ventilated for
up to 72 h. Twenty-four hours after bacterial challenge, animals were random-
ized to receive 2-day treatment with either intravenous saline (untreated) or 25
to 50 mg of C/T per kg body weight (AEAT) or 200 to 225 mg of TZP per kg
(IEAT) every 8 h. The primary outcome was the P. aeruginosa burden in lung tis-
sue and the histopathology injury. P. aeruginosa burden in tracheal secretions
and bronchoalveolar lavage (BAL) fluid, the development of antibiotic resistance,
and inflammatory markers were secondary outcomes. Overall, P. aeruginosa lung
burden was 5.30 (range, 4.00 to 6.30), 4.04 (3.64 to 4.51), and 4.04 (3.05 to 4.88)
log10CFU/g in the untreated, AEAT, and IEAT groups, respectively (P  0.299),
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without histopathological differences (P  0.556). In contrast, in tracheal secre-
tions (P  0.001) and BAL fluid (P  0.002), bactericidal efficacy was higher in the
AEAT group. An increased MIC to TZP was found in 3 animals, while resistance
to C/T did not develop. Interleukin-1 (IL-1) was significantly downregulated by
AEAT in comparison to other groups (P  0.031). In a mechanically ventilated
swine model of XDR P. aeruginosa pneumonia, appropriate initial treatment with
C/T decreased respiratory secretions’ bacterial burden, prevented development
of resistance, achieved the pharmacodynamic target, and may have reduced sys-
temic inflammation. However, after only 2 days of treatment, P. aeruginosa tissue
concentrations were moderately affected.
KEYWORDS Pseudomonas aeruginosa, animal models, appropriate empirical
antimicrobial treatment, mechanical ventilation, pneumonia
Nosocomial pneumonia is one of the most common hospital-acquired infections,associated with substantial morbidity and attributable mortality higher than 10%
(1–3). Pseudomonas aeruginosa is one of the most common causative pathogens,
causing life-threatening conditions (4). The latest guidelines strongly recommend
appropriate empirical treatment based on local etiology and the presence of risk factors
for multidrug-resistant and extensively drug-resistant (MDR/XDR) organisms (2, 5). In
patients with suspected nosocomial pneumonia, recommended empirical therapy
includes coverage for P. aeruginosa with an antipseudomonal -lactam and/or a
fluroquinolone (2). Nevertheless, due to increasing resistance to fluroquinolones and
traditional -lactams, appropriate empirical therapy is increasingly difficult. Specifically,
inappropriate empirical antimicrobial therapy (IEAT) indicates the empirical antimicro-
bial regimen administered during the first 48 to 72 h after suspecting nosocomial
pneumonia that was not active against the identified pathogen. The rate of IEAT for the
treatment of nosocomial pneumonia is up to 60% (6), and it is associated with increased
mortality and length of stay (7). Furthermore, achieving adequate antimicrobial pul-
monary concentrations is challenging (8), due to high MICs and pharmacokinetic
variations among patients with acute illnesses (9, 10).
In this scenario, ceftolozane/tazobactam (C/T) is a novel -lactam/-lactamase
inhibitor combination antimicrobial agent which has been approved for the treatment
of complicated urinary tract and intraabdominal infections in adults (11, 12) and was
recently approved by the American Food and Drug Administration for the treat-
ment of nosocomial pneumonia (12). Ceftolozane is a fifth-generation cephalospo-
rin that is active against P. aeruginosa and has a notable stability against pseu-
domonal AmpC-mediated resistance (13, 14), while tazobactam extends efficacy
against many extended-spectrum -lactamase-producing Enterobacteriaceae (15). Pre-
liminary in vitro studies have shown activity against up to 85% of P. aeruginosa isolates
that are nonsusceptible to ceftazidime, meropenem and piperacillin/tazobactam (16).
The drug primarily distributes into the extracellular fluid with good lung penetration
(17, 18). While the approved dose for other infections is 1 g, with 0.5 g tazobactam,
every 8 h (12), a larger dose of up to 3 g (1 g tazobactam) every 8 h has been approved
for nosocomial pneumonia in order to achieve 90% probability of target attainment
against pathogens with a MIC up to 8 mg/liter (19). A recently concluded large
multicenter, randomized, controlled phase III (ASPECT-NP) trial in ventilated patients
with nosocomial pneumonia compared the antibacterial efficacy of C/T and mero-
penem. C/T was noninferior to meropenem in treating pneumonia (weighted treatment
difference (1.1%; [95% confidence interval (CI) – 6.2 to 8.3]) (20). Although a novel
antimicrobial with a higher susceptibility rate, such as C/T, may improve clinical
outcome, further preclinical and clinical evaluations are essential to outline the role in
empirical antimicrobial therapy for nosocomial pneumonia in comparison to other
first-line antipseudomonal antibiotics.
Therefore, herein, we present a prospective randomized study in a validated animal
model of severe P. aeruginosa pneumonia to study the short-term benefits of appro-
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priate empirical antimicrobial treatment (AEAT) with C/T in comparison with IEAT with
piperacillin/tazobactam (TZP), a -lactam/-lactamase inhibitor commonly used for
suspected nosocomial pneumonia (2, 5). The primary aim of the study was to investi-
gate bactericidal activity and lung histopathological severity during the first 48 h of treat-
ment (i.e., traditional methods take at least 48 h to provide a final results) and to develop
further insights into the benefits after a short period of AEAT to life-threatening pulmonary
infections.
RESULTS
Preliminary study. As shown in Fig. S1 in the supplemental material, clinical,
microbiological, and histological findings confirmed severe pneumonia in animals
included in preliminary analyses. We initially assessed C/T concentrations of 30/15 and
60/30 mg/kg, and TZP of 100/12.5 mg/kg and 200/25 mg/kg, as 1-h infusion every 8 h
(q8h), in healthy animals (Table S1). Following dose adjustment, confirmatory pharma-
cokinetic studies in infected animals showed that 60 mg/kg of ceftolozane achieved
epithelial lining fluid (ELF) area under the concentration-time curve from 0 to 8 h
(AUC0 – 8h) slightly higher than 200 mg/h/liter, while 200 mg/kg of piperacillin achieved
100 to 140 mg/h/liter (Table S2). Therefore, doses of 50 mg/kg of ceftolozane and
200 mg/kg of piperacillin were selected to provide an ELF exposure similar to that
achieved in humans following a dose of C/T of 3 g and TZP of 4.5 g every 8 h.
Main study. Out of 23 animals, 21 completed the study. Two animals were eutha-
nized shortly after the first administration of antibiotics, for severe respiratory and
hemodynamic instability, and were not included in the analysis.
Primary outcome. A total of 105 pulmonary lobes were analyzed. Qualitative and
quantitative lung culture results are summarized in Fig. 1. After 48 h of treatment, the
median (interquartile range [IQR]) P. aeruginosa tissue concentrations were 4.04 (range,
3.64 to 4.51; AEAT animals), 4.04 (range, 3.05 to 4.88; IEAT animals), and 5.30 (range,
4.00 to 6.30; untreated animals) log10 CFU per ml (P  0.299) (Fig. 1A). Notably, animals
with appropriate empirical C/T therapy presented the highest number of uncolonized
lobes (20%), while the percentage of lung tissue samples with positive cultures for P.
aeruginosa in the untreated and IEAT groups was 97.14% and 88.57%, respectively
(P  0.033) (Fig. 1B). Figure 1 also shows the results of histopathological analysis of the
105 lung tissue samples evaluated. No significant differences were found between
histological features among therapeutic groups (P  0.556). The composite histological
and bacterial burden score was 6.71 (range, 5.00 to 8.36], 5.86 (range, 5.36  6.86), and
5.14 (4.29 to 6.57) in the untreated, appropriate, and inappropriate groups, respectively
(P  0.460). Lung appearance and lung/body weight ratio are reported in Fig. S2.
Secondary outcomes of microbiology assessments. Figure 2 depicts tracheal
secretions and bronchoalveolar lavage (BAL) fluid P. aeruginosa burden throughout the
study. P. aeruginosa colonization within tracheal secretions differed among study
groups (P  0.001). Specifically, appropriate empirical treatment with C/T caused a
significant reduction in P. aeruginosa concentrations in tracheal secretions in compar-
ison to untreated (P  0.001) and TZP-treated animals (P  0.048) at 48 h and at the end
of the study (P  0.001). IEAT with TZP had a marginal effect versus control animals
after 48 h of treatment (P  0.002). P. aeruginosa concentration in BAL fluids varied
among study groups (P  0.002). Indeed, AEAT with C/T yielded improved antipseu-
domonal effects in BAL fluid in comparison to those in the untreated (P  0.004) and
IEAT groups (P  0.018), while no differences were found between untreated and
inappropriately TZP-treated animals throughout the experiment. P. aeruginosa bacte-
remia was detected in only one, untreated animal.
Importantly, P. aeruginosa augmented its resistance to TZP following 48 h of treat-
ment; in particular, a 4-fold increase in the TZP MIC was found in P. aeruginosa isolates
from 3 animals (42.9%) (Fig. 2C). Conversely, P. aeruginosa isolates under appropriate
initial therapy with C/T did not yield any increase in P. aeruginosa resistance (P  0.030).
Secondary outcomes of inflammatory markers. The development of pneumonia
substantially affected systemic and pulmonary cytokines. Initial P. aeruginosa challenge
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resulted in a significant increase in all assessed serum cytokines, except interleukin-8
(IL-8), while in BAL fluid, IL-1 and IL-8 were the only upregulated cytokines (Fig. S3).
Antibiotic treatments decreased IL-1 and IL-6 (Fig. 3A and B). In particular, serum IL-1
was significantly downregulated by appropriate C/T therapy (P  0.031), returning to
baseline levels after 48 h of treatment, compared to untreated (P  0.081) and IEAT
animals (P  0.049). Likewise, serum IL-6 was upregulated upon pneumonia diagnosis
and showed a downward trend throughout the treatment period (P  0.001) but
without showing significant differences between groups.
FIG 1 Pulmonary burden and severity of histopathological findings among treatment groups. (A) Box plots showing the P. aeruginosa concentration in lung
tissue among study groups. There was no statistically significant difference in bacterial burden between study groups (P  0.299). Horizontal bars represent the
median, boxes represent the interquartile range, whiskers represent the range, and the plus sign denotes the mean. (B) Semiquantitative microbiological
assessment of lung tissue among study groups. Each dot represents the degree of P. aeruginosa colonization in each lobe, defined as no growth, P. aeruginosa
colonization  3 log10 CFU/g, and pneumonia with histological confirmation and P. aeruginosa concentration  3 log10 CFU/g. Of note, significant differences
were found between study groups (21 pigs; 105 lobes; P  0.033). In particular, the percentage of colonization in the AEAT group was significantly lower than
that of the untreated (P  0.028) and IEAT groups (P  0.045). In contrast, no differences in colonization proportions were found between study groups
(P  0.194). No lobe correlation was found. (C) Results are displayed as the percentage of scores of the five lobes per animal. No differences were found between
study groups (21 pigs; 105 lobes; P  0.556). (D) Three specific histopathological patterns were found only in untreated and IEAT groups as follows: the
histopathology pattern characterized by pathogens and inflammatory cells within the alveolar space (D1 and D2), organizing pneumonia (D3), and alveolar
diffuse damage (D4). (D1) An inflammatory infiltrate composed of polymorphonuclear leukocytes is observed, located adjacent to the interlobular septa (white
arrow), preserving the centrilobular zone (asterisk). The affected areas showed an effacement of the alveolar architecture, with hemorrhagic foci (black arrow)
(4 magnification). (D2) The edematous interlobular septum separates four congestive lobules. In the lower two, an inflammatory infiltrate composed of
polymorphonuclear leukocytes is observed, which tends to be located adjacent to the interlobular septa (white arrow). The centrilobular zone shows a milder
acute inflammatory infiltrate that occupies the alveolar spaces, preserving the alveolar septa (black asterisk). Areas of alveolar edema can be seen (white asterisk)
(10 magnification). (D3) Dense interstitial proliferation of fibroblastic appearance that caused a decrease of the alveolar lumina, which appeared to be
occupied by polymorphonuclear leukocytes and histiocytes. The foci of interalveolar fibroblast buds are spotted (white asterisk) (20 magnification). (D4) The
presence of fibrinoid material intermingled with blood (white arrow) suggested an initial stage of organization of alveolar hemorrhage (20 magnification).
AEAT, appropriate empirical antimicrobial therapy; IEAT, inappropriate empirical antimicrobial therapy; RUL, right upper lobe; RML, right medium lobe; RLL, right
lower lobe; LUL, left upper lobe; LLL left lower lobe.
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FIG 2 Tracheal secretions and bronchoalveolar lavage fluid P. aeruginosa burden and resistance devel-
opment after antimicrobial exposure. P. aeruginosa concentrations (log10 CFU/ml) are plotted as line
graphs, reporting means and standard errors of the means (SEM). (A) Tracheal secretions. P. aeruginosa
concentrations differed among study groups (P  0.001) and throughout the experiment (P  0.001).
Post hoc comparisons showed a significant reduction compared to controls at 48 h (P  0.001) and at the
end of the study (P  0.001). The double dagger shows a significant reduction of P. aeruginosa burden
in AEAT with C/T versus IEAT with TZP at 48 h (P  0.048) and 72 h (P  0.001). (B) Equally, P. aeruginosa
concentrations in BAL fluids varied among treatment groups and times of assessments (P  0.002).
Essentially, the P. aeruginosa concentration was significantly decreased with AEAT compared to the
untreated (P  0.0004) and IEAT (P  0.018) groups at 72 h. Before treatment started, all depicted means
were not statistically different in both matrixes. Of note, the statistical significance of AEAT and IEAT
groups against the untreated group is shown by an asterisk and a dagger, respectively. Differences
between AEAT and IEAT are displayed by the double dagger. (C) Changes in ceftolozane MIC (left) and
piperacillin MIC (right) are shown in this aligned dot before-and-after graph. Each dot represents the MIC
of P. aeruginosa isolates at pneumonia diagnosis and after treatment for each subject in each study
group. A significant effect of piperacillin exposure was observed in isolates from the IEAT group
compared with those from the AEAT group. The dashed line displays the ceftolozane and piperacillin MIC
of the inoculated strain. AEAT, appropriate empirical antimicrobial therapy; IEAT, inappropriate empirical
antimicrobial therapy; C/T, ceftolozane/tazobactam; TZP, piperacillin/tazobactam.
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FIG 3 Serum inflammatory markers. Box plots show the fold change from baseline (log2) among study groups. Horizontal bars represent the median, boxes
represent the interquartile range, and whiskers represent the range. IL-1 varied significantly among study groups (P  0.031) and throughout the study time
(P  0.001). Indeed, post hoc comparisons confirmed that IL-1 was downregulated by AEAT with C/T at 72 h in comparison with untreated (P  0.081) and
IEAT TZP-treated animals (P  0.049). Similarly, although no statistical significance was found among study groups, IL-6 showed a downward trend
throughout the study time (P  0.001). In contrast, IL-8, IL-10, and TNF- did not vary among study groups and times of assessments. AEAT, appropriate
empirical antimicrobial therapy; IEAT, inappropriate empirical antimicrobial therapy; IL, interleukin; TNF-, tumor necrosis factor alpha; C/T, ceftolozane/
tazobactam; TZP, piperacillin/tazobactam.
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BAL fluid IL-1, IL-6, and IL-8 (Fig. S4) peaked post-bacterial burden and remained
relatively upregulated thereafter, without differences between groups. Of note, in BAL
fluid, IL-8 presented a higher concentration than in serum, while IL-6 showed the
opposite trend.
Secondary outcomes of pharmacokinetics. Antibiotic concentrations were quanti-
fied in blood and BAL fluid in all treated animals. Table 1 and Fig. S5 describe the
plasma and ELF pharmacokinetic profiles of ceftolozane and piperacillin. As expected,
due to MIC disparities, ceftolozane achieved a higher percentage of time above MIC
(%T  MIC) in both matrixes than piperacillin.
Clinical variables, hemodynamics, and biochemistry. Table 2 depicts the dynam-
ics of clinical, hemodynamics, and biochemistry variables. Neither main clinical nor
hemodynamics variables were affected by antimicrobial treatments, yet those param-
eters changed significantly over the course of the study. The quantity and presence of
purulent tracheal secretions were significantly lower in the AEAT group. A trend toward
a higher vasopressor dependency index was found in the IEAT with TZP and untreated
groups. No differences were found in creatinine levels among study groups, while liver
enzymes were significantly higher in the control group, and gamma-glutamyl trans-
ferase slightly increased in the AEAT with C/T group.
Pulmonary mechanics and gas exchange. Figure S6 shows changes in pulmonary
variables throughout the study period. Oxygenation differed between groups and
throughout the study period (P  0.001). In particular, the ratio of partial pressure of
oxygen per inspiratory fraction of oxygen was drastically impaired at 24 h in all groups
(P  0.001) and differed between study groups at the end of the study (P  0.018). This
variation was mainly driven by the unresolved impairment in gas exchange in un-
treated animals. Other variables, except for the peak airway pressure, were not affected
by study treatments.
DISCUSSION
In this randomized experimental study in animals with severe pneumonia caused by
XDR P. aeruginosa, we demonstrated that in comparison with IEAT with TZP, appropri-
ate empirical antimicrobial therapy with humanized regimens of C/T for 48 h only
achieved the following results: (i) enhanced bactericidal effect in tracheal secretions
and BAL fluids, (ii) hindered emergence of resistance, (iii) achieved pharmacodynamic
target, and (iv) diminished systemic inflammation, as specifically shown by reduced
IL-1. However, the short course of therapy did not significantly reduce lung tissue
burden among the study groups. Similarly, both antimicrobial treatments had marginal
effects on clinical variables.
Severe P. aeruginosa pneumonia is a life-threatening infection most commonly
TABLE 1 Ceftolozane and piperacillin pharmacokinetics and pharmacodynamics in infected animalsa
Ceftolozane (AEAT) (n  6; 50 mg/kg) Piperacillin (IEAT) (n  6; 200 mg/kg)
Pharmacokinetic parameters
CL (liters/h) 4.33 (4.06–4.57) 7.62 (6.48–8.11)
Vc (liters) 9.78 (9.40–10.34) 10.35 (9.07–12.50)
VELF (liters) 2.06 (1.48–2.71) 2.42 (1.35–7.85)
Kcp (h1) 0.10 (0.05–0.16) 0.16 (0.10–0.23)
Kpc (h1) 0.58 (0.36–0.83) 0.88 (0.52–1.68)
Pharmacodynamic indices
Plasma fAUC (mg/h/liter) 358.40 (331.26–370.58) 808.73 (733.55–974.58)
ELF fAUC (mg/h/liter) 267.95 (201.48–378.32) 592.48 (430.16–711.73)
Penetration (%) 88.82 (71.08–105.77) 74.92 (47.45–94.69)
Plasma fT  MIC (%) 100.00 (100.00–100.00) 46.88 (42.50–53.13)
ELF fT  MIC (%) 96.25 (96.25–97.19) 50.63 (35.94–56.88)
aData are reported as median and interquartile range (IQR) (25th to 75th percentile). CL, clearance; Vc, volume of distribution of the central compartment; VELF, volume
of distribution of the peripheral epithelial lining fluid (ELF) compartment; Kcp, transfer rate constant from the central compartment to the peripheral ELF
compartment; Kpc, transfer rate constant from the peripheral ELF compartment to the central compartment; fAUC, free area under the curve to MIC ratio over first 8
h; fT  MIC, free time above the MIC over first 8 h.
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encountered in intensive care unit (ICU) patients (21). The empirical antimicrobial
regimen (that is, therapy administered for 48 to 72 h until pathogen identification and
in vitro susceptibility data are available) is usually categorized as inappropriate when it
did not include any antibiotic showing in vitro activity against the isolated bacteria.
Some authors have included dosing, route, or duration considerations within the
definition. In these settings, the growing prevalence of antibiotic-resistant P. aeruginosa
strains is posing as a major threat for initial antimicrobial treatment accuracy (22).
Indeed, the frequency of IEAT for the treatment of nosocomial pneumonia is up to 60%
(6), and in the subpopulation of pneumonia caused by MDR P. aeruginosa, it is up by
70% (23).
Early initiation of appropriate antibiotic therapy might be a key factor in improving
outcomes in patients with nosocomial pneumonia. However, antibiotic selection is
challenging, given the aim to strike a balance among administering adequate empirical
antibiotic treatment, minimizing the risk of increasing ecological pressure for resistance
selection, and decreasing the likelihood of side effects. International guidelines for
nosocomial pneumonia consider the appropriateness of the empirical treatment to be
important to the outcome, though, and place it in higher consideration as a result
compared to the emergence of resistance or side events (2, 5).
Nevertheless, the degree of influence of IEAT on mortality risk from MDR/XDR
infections in critically ill patients remains controversial; conclusions from clinical studies
have left an unanswered question. Claeys et al. recently reported that 44.6% patients
with ICU-acquired lower respiratory infections caused by Gram-negative pathogens
were administered IEAT (24). In this study, cefepime (45.1%) and TZP (36.8%) were the
most frequent empirical treatments, and the lack of in vitro susceptibility was the
primary cause of IEAT (24). As a consequence, IEAT translated into significantly higher
lengths of stay and an associated economic burden; however, clinical failure and
all-cause mortality were not significantly higher than compared to patients with







(AEAT) (n  7)
Inappropriate







Body temp (°C) 37.7  0.3 38.3  0.2 38.1  0.2 38.2  0.3 0.680 0.400
WBC ( 109/liter) 9.4  0.8 21.7  3.3 18.7  4.8 18.5  4.9 0.822 0.002
Semiquantitative tracheal secretions 0.3  0.7 1.7  0.4 1.2  0.3b 1.4  0.2 0.018 0.560
Purulent secretions (%) 4.8 92.9 73.2c 92.9 0.002
Hemodynamics
Heart rate (beats per minute) 74.0  5.6 68.0  11.8 68.4  12.3 76.7  11.7 0.427 0.001
Mean arterial pressure (mm Hg) 85.8  3.7 74.1  4.4 71.7  3.1 72.6  3.3 0.815 0.032
Mean pulmonary arterial pressure (mm Hg) 16.1  2.2 22.3  1.9 21.7  0.9 22.1  1.2 0.936 0.001
Cardiac output (liters/min) 2.8  0.1 4.0  0.3 3.8  0.6 4.0  0.6 0.926 0.008
VDI (mm Hg1) 0 0.43  0.13 0.55  0.32 0.91  0.31 0.472 0.001
SVR (dynes/s/cm5) 2450  165 1442  102 1550  361 1393  247 0.860 0.002
PRV (dynes/s/cm5) 284.7  15.1 214.5  25.4 231.2  31.3 227.2  25.4 0.653 0.390
Biochemistry analysis
Creatinine (mg/dl) 1.2  0.02 1.3  0.03 1.2  0.05 1.4  0.06 0.347 0.243
ALT (IU/liter) 34.7  1.7 31.6  2.8 21.8  1.8b 24.1  3.6 0.021 0.394
GGT (IU/liter) 69.9  16.5 50.5  5.3 51.7  3.9 36.6  7.7d 0.020 0.212
Alkaline phosphatase (IU/liter) 178.0  25.4 135.5  25.7 159.5  28.4 158.0  36.0 0.371 0.001
Total bilirubin (mg/dl) 0.20  0.03 0.27  0.08 0.20  0.07 0.39  0.15 0.133 0.001
aData are reported as the mean  standard deviation of the level from each variable during 48 h of treatment. Clinical and hemodynamics values were recorded
every 6 h, while biochemistry analyses were performed every 12 h. The P value stands for the probability of differences between treatment groups (i.e., untreated,
AEAT, and IEAT groups). Intergroup comparisons with Bonferroni corrections AEAT, appropriate empirical antimicrobial therapy; IEAT, inappropriate empirical
antimicrobial therapy; WBC, white blood cells; VDI, vasopressor dependency index; SVR, systemic vascular resistance; PVR, pulmonary vascular resistance; ALT, alanine
aminotransferase; GGT, gamma-glutamyl transferase.
bP  0.05 versus untreated.
cP  0.05 versus untreated and IEAT.
dP  0.05 versus untreated and AEAT.
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appropriate empirical treatment (24). Vasudevan and colleagues presented similar
findings, reporting that IEAT was not an independent risk factor for ICU mortality
among critically ill patients with pneumonia caused by MDR/XDR pathogens (25). In
contrast, a prospective cohort study comparing appropriate treatment and IEAT in
patients with a strong suspicion of ventilator-associated pneumonia (VAP) showed that
the mortality rate (38%) was lower in the former group compared to those receiving
IEAT (91%) (26). A separate prospective cohort of patients with VAP reported similar
findings, with the mortality rate lower in patients undergoing appropriate treatment
(20%) than that of patients receiving IEAT (47%) (27).
As a result, association between IEAT and mortality in patients with nosocomial
pneumonia continues to be counterintuitive (28). Additionally, the beneficial impact on
outcomes in patients with nosocomial pneumonia within the first 48 to 72 h of
admission has not been studied yet. We therefore aimed to analyze what happened
during this window, that is, between first sampling and the determination of microbi-
ological results dependent on the appropriateness of an empirical treatment. Our
results strengthen the hypothesis that early initiation of appropriate antibiotic therapy
is a fundamental factor for improved outcomes in nosocomial pneumonia. Compound-
ing this is a study by Mortensen et al., in which they reported that AEAT was associated
with decreased mortality at 48 h in patients with community-acquired pneumonia (29).
Although differences in mortality were not found in our study, perhaps due to a small
sample size, significant burden reduction in tracheal secretions and BAL fluids were
detected when animals received AEAT. These reductions may indicate the first visible
step of infection eradication during the administration of appropriate empirical ther-
apy, particularly before any observation of a decrease in lung tissue burden can be
made.
As mentioned above, short-term benefits of appropriate empirical treatment in-
cluded the attainment of a pharmacodynamics target, as well as the prevention of
resistance development. Ceftolozane has been demonstrated to be perhaps more
stable against the most common resistance mechanisms of P. aeruginosa, which are
driven by mutation, upregulation, or hyperproduction, i.e., AmpC, efflux pumps, or
OprD (14, 30). Remarkably, in our study, C/T prevented resistance development in the
AEAT group, whereas the MIC increased substantially after only 48 h of treatment with
TZP. Differences between the AEAT and IEAT groups in target attainment for pharma-
codynamics (i.e., %T  MIC), which is also directly related to bactericidal efficacy, may
also explain disparities in resistance development dynamics. Moreover, the mutation
frequency for TZP was considerably higher than for C/T in our strain, which might also
be linked to the TZP MIC increase (see “Additional Methods” in the supplemental
material). It is of equal importance to highlight that using broad-spectrum antibiotics
for initial therapy in order to avoid IEAT may indeed lead to a worsening antimicrobial
resistance burden due to selection of even more resistant pathogens. The development
of novel antibiotics is therefore necessary if clinicians are to have an increased likeli-
hood of choosing an active, effective agent for empirical therapy of nosocomial
pneumonia. Similarly, the development of rapid, low-cost diagnostic microbiological
tools that allow the prompt use of narrow-spectrum antibiotics is equally important.
In addition, our study sheds light on the effects of C/T in a large animal model that
closely resembles critically ill patients with severe MDR/XDR P. aeruginosa pneumonia.
Currently, therapeutic options for MDR/XDR Gram-negative pathogens are extremely
limited (31). C/T treatment, however, appears to be a promising option with excellent
in vitro (32) and in vivo efficacy, enabling the attainment of pharmacodynamic targets
in central and peripheral compartments (19). Ceftolozane has shown excellent anti-
pseudomonal efficacy, even against MDR/XDR strains (13, 33). Interestingly, in hospi-
talized patients with pneumonia, C/T inhibited 94% of P. aeruginosa isolates obtained
from these individuals, while TZP demonstrated activity against only 69% (33). These
observations highlight current clinical limitations of the latter, relatively longstanding,
antibiotic. Moreover, an increase in carbapenem-resistant P. aeruginosa isolates has
been observed, comprising 26% of isolates nonsusceptible to meropenem. In this
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context, C/T is likely to be selected for achieving AEAT and should be preserved for
MDR/XDR pathogens.
This study presents some limitations that deserve further discussion, though. First,
TZP could have yielded subinhibitory concentrations in ELF and ultimately facilitated
emergence of resistance. Our methods nevertheless attempted to replicate current
clinical conditions; in IEAT cases, especially, the attainment of pharmacodynamic
targets in central and peripheral compartments was usually unexpected. The rationale
behind selecting a particular strain in our study was to represent this phenotypic profile
for which C/T is likely to be chosen for empirical treatment in patients with resistance
risk factors and in those individuals admitted to ICUs with high MDR/XDR prevalence
(i.e., nonsusceptibility to -lactams, including carbapenems). Second, the corroboration
of secondary outcomes was limited by the use of only one P. aeruginosa strain and the
length of the therapy. Even though both antimicrobials adequately penetrated lung
tissue, pulmonary infection was exceedingly severe and marginally affected by the
short course of treatment. We may therefore lack accuracy in detecting potential
differences in lung tissue between study groups. Nevertheless, we wanted to reproduce
the clinical setting, where 48 h after initiation of the empirical treatment, pathogen
identification and in vitro susceptibility data would be available, and the clinician would
have the possibility to switch the antibiotic therapy. Moreover, a major strength of our
study was the survival rate of more than 90% of the animals evaluated. This fact
afforded comprehensive appraisal of infection dynamics and response to treatment.
Third, in comparison with phase I studies of healthy volunteers, ceftolozane penetration
into ELF of our animals achieved greater figures (17); however, as demonstrated in our
preliminary analysis, a C/T dosage of 50 mg/kg achieved similar results as those
reported in humans. Differences in C/T pharmacokinetics in severely infected lungs
could explain these findings, which are likely to be reproducible in critically ill patients
with severe pneumonia. Indeed, the C/T concentrations in ELF of our swine model
exceeded the MIC for 100% of the dosing interval, with a MIC of 4 mg/liter, analogous
to previous observations in humans (34). Similarly, the piperacillin ELF AUC0 – 8h showed
greater figures than expected based on preliminary studies. This unexpected finding
could be explained by highly variable intrapulmonary exposure, unrelated to plasma
exposure, as previously detailed by Felton et al. (35). Finally, within our setting, animals
did not have comorbidities and were in deep sedation throughout the study. These
dissimilarities when considering critically ill patients with nosocomial pneumonia are
noteworthy to mention.
Conclusions. In a mechanically ventilated swine model of XDR P. aeruginosa pneu-
monia, appropriate initial treatment with C/T decreased respiratory secretions’ bacterial
burden, prevented development of resistance, achieved the pharmacodynamic target,
and may reduce systemic inflammation. However, after only 2 days of treatment, P.
aeruginosa tissue concentrations were moderately affected. These data imply several
potential benefits of AEAT and call for further experimental and clinical studies to fully
determine the short-term implications of IEAT. The translation of our findings to clinical
practice is obviously encouraging the use of new antibiotics against MDR/XDR bacteria
as soon as possible. This problem is be solved not with conventional cultures but
probably with the implementation of rapid molecular techniques that can detect
resistance.
MATERIALS AND METHODS
This study was conducted at the Division of Animal Experimentation, Hospital Clinic, Barcelona,
Spain. The study protocol was approved by the Animal Experimentation Ethics Committee of the
University of Barcelona (reference number 9772).
Preliminary studies. We employed a porcine model of severe P. aeruginosa, as previously described
(36). In order to catch the potential scenario of empirical antimicrobial therapy failure, we selected an
XDR (-lactam nonsusceptible, including carbapenems) P. aeruginosa strain not susceptible to TZP (MIC,
64/4 mg/liter) and at the upper range of the C/T susceptibility profile (MIC, 4/4 mg/liter) (33). Full
antimicrobial susceptibility is presented in Table S3. Resistance mechanisms, mutation frequencies, and
clinical sources are also described (see “Additional Methods” in the supplemental material). Two animals
were used to confirm the pneumonia clinically, microbiologically, and histologically. Single-dose phar-
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macokinetic studies of C/T and TZP were performed in healthy animals to identify humanized doses. In
particular, we aimed at achieving ELF ceftolozane AUC0 – 8h of about 150 to 175 mg/h/liter (i.e., 3 g in
humans) (19) and ELF piperacillin AUC0 – 8h of about 100 to 140 mg/h/liter (i.e., 4.5 g in humans) (37). The
pharmacokinetic parameters were derived individually for each pig, and the AUC0 – 8h was calculated by
using the linear trapezoidal rule. Confirmatory pharmacokinetic studies were performed in infected
animals.
Main study. Twenty-three large white Landrace female pigs (32.9  1.7 kg; Specipig, Barcelona,
Spain) were intubated and mechanically ventilated up to 76 h. Sedatives and analgesics were adminis-
tered as previously described (38). Pneumonia was developed by intrabronchial inoculation of 15 ml of
7 log10 CFU/ml of the aforementioned P. aeruginosa strain (36). After 24 h, pneumonia was confirmed
(see “Additional Methods” in the supplemental material) and treatment commenced. Based on the
results of pharmacokinetic studies, animals were randomized to receive, every 8 h, intravenous saline
solution (untreated) or 50 mg/kg of ceftolozane and 25 mg/kg of tazobactam (AEAT) or 200 mg/kg of
piperacillin and 25 mg/kg of tazobactam (IEAT) over 1 h. Figure S7 displays the study design and
assessment plan.
Primary outcome. The animals were euthanized 76 h after tracheal intubation (4 h after the last
antimicrobial dose), and quantitative pulmonary cultures were performed (38). Furthermore, each lobe
was biopsied, and the pneumonia severity score was computed (39). Semiquantitative evaluation of each
specimen was derived from the sum of the worst histological and bacterial burden scores (40).
Investigators were blinded to the treatment allocation.
Secondary outcomes. Every 24 h, we cultured tracheal secretions, BAL fluid, and blood. In addition,
P. aeruginosa resistance to C/T and TZP was quantified. Prior to bacterial challenge, and every 24 h
thereafter, interleukin-1 (IL-1), IL-6, IL-8, IL-10, and tumor necrosis factor- (TNF-) were quantified in
serum and BAL fluids by bead-based multiplex assays with Luminex technology (Millipore Iberica, S.A.,
Madrid, Spain) (41). The antimicrobial concentration was measured in plasma and BAL fluids through
high liquid chromatography at baseline and at 1, 2, 4, 6, and 8 h thereafter (42–44). Protein binding was
assessed in duplicate, and ELF concentrations were determined using urea concentration as an endog-
enous marker (45). A 2-compartment model for each drug was performed using the nonparametric
adaptive grid algorithm (46, 47). Hemodynamic parameters, pulmonary variables, gas exchange, and
urinary output were evaluated throughout the study; ventilator settings were adjusted and clinical sepsis
guidelines applied to achieve ventilatory and hemodynamic stability (38).
Statistical analysis. Continuous variables were described as means and standard deviation (SD) or
median (interquartile range [IQR]; 25th to 75th percentile), while categorical variables were described as
counts and percentages. The normality of the residuals of the mixed models was assessed. In the case of
normal distribution, differences among study groups and/or times of assessments of continuous variables
were analyzed through a linear mixed-effects models (MIXED) procedure based on a repeated measures
approach (restricted maximum likelihood analysis). For nonparametric distributions, the Kruskal-Wallis test
was used. Categorical variables were analyzed using the Chi-square test. Each pairwise comparison was
corrected using the Bonferroni test. A two-sided P value of 0.05 was considered statistically significant. All
statistical analyses were performed using IBM SPSS Statistics 21.0 (Armonk, NY, USA).
SUPPLEMENTAL MATERIAL
Supplemental material is available online only.
SUPPLEMENTAL FILE 1, PDF file, 1.1 MB.
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